Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 6;10:315. doi: 10.3389/fimmu.2019.00315

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Oostenbrink, Jol-van der Zijde, Kielsen, Jansen-Hoogendijk, Ifversen, Müller, Lankester, van Halteren, Bredius, Schilham and van Tol.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Immune cell recovery post-HSCT in ATG-FRES (Fresenius) treated patients in comparison with high (ATG-GENZ-high) and low dose (ATG-GENZ-low) ATG-GENZ (Genzyme) treated patients. CD3 T-cell and CD4 and CD8 T-cell subset numbers differed significantly at one month post-HSCT between the two ATG treated groups. ATG-GENZ-high patients recovered significantly slower for CD3, CD4, and CD8 compared to the ATG-FRES and ATG-GENZ-low treated patients. In contrast to the T-cell recovery, NK-cells recovered fast after HSCT reaching normal levels within 1 month. The highest level of NK-cell numbers were observed at one month in the ATG-GENZ-high group. B-cell recovery in all ATG groups returned to normal levels at 6 months post-HSCT with a significantly higher number of B-cells at 2 and 3 months in the ATG-GENZ-high compared to the ATG-GENZ-low and ATG-FRES treated patients, respectively. Dotted horizontal lines represent the 5th and 95th percentiles of cell numbers in 28 healthy age-matched donors. Gray line: patients transplanted for acute leukemia with a graft from an HLA-identical sibling donor without receiving ATG in the conditioning.